Predictive Risk Factors for One-year Mortality in Idiopathic Inflammatory Myopathy Patients with Interstitial Lung Disease: A Retrospective, Single-center Cohort Study

Overview

Journal Arch Rheumatol

Specialty Rheumatology

Date 2024 Jun 27

PMID 38933718

Authors

Minna Jiang

Xiaohong Wen

Sisi Xia

Yiqun Guo

Yu Bai

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aimed to analyze the risk factors for mortality of idiopathic inflammatory myopathy (IIM) patients admitted with interstitial lung disease (ILD) to guide rapid and accurate judgment of clinical prognosis.

Patients And Methods: This retrospective, single-center cohort study was conducted with 135 participants (37 males, 98 females; mean age: 54.8±11.1 years; range, 24 to 85 years) between June 1, 2016, and June 30, 2021. The participants were categorized into the survival group (n=111) and nonsurvivors (n=24) according to whether they survived during the one-year follow-up. The independent risk factors for mortality in one year after discharge were analyzed. Receiver operating characteristic curve analysis was used to determine the accuracy of oxygenation index at baseline combined with pulmonary infection (PI) at follow-up to indicate death in IIM-ILD patients.

Results: Compared to the survival group, nonsurvivors were older (p=0.006) and had a higher proportion of anti-MDA5 (melanoma differentiation-associated protein 5) positivity (p<0.001). The ILD duration was shorter (p=0.006), the oxygenation index was lower (p<0.001), and the intensive care unit occupancy rate (p<0.001) and ventilator utilization rate (p<0.001) were elevated in nonsurvivors compared to the survival group. Oxygenation index at baseline (odds ratio [OR]=1.021, 95% confidence interval [CI]: 1.001-1.023, p=0.040) and PI (clinical judgment) at follow-up (OR=16.471, 95% CI: 1.565-173.365, p=0.020) were found as independent risk factors for death in the year after discharge in IIM inpatients with ILD. An oxygenation index ≤279 mmHg at baseline combined with PI at follow-up exhibited a promising predictive value for all-cause death in IIM-ILD patients within one year.

Conclusion: Oxygenation index at baseline and PI during follow-up were independent risk factors for death of IIM-ILD patients within one year after discharge. Patients with an oxygenation index ≤279 mmHg at baseline had an increased risk of death once they developed PI during the one-year follow-up.

References

Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T . Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014; 15:109. PMC: 4243719. DOI: 10.1186/s12931-014-0109-y. View

Chen I, Tsai W, Wu Y, Luo S, Ho H, Liou L . Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology (Oxford). 2010; 49(12):2429-37. DOI: 10.1093/rheumatology/keq279. View

Liu W, Peng L, Hua S . Clinical significance of dynamic monitoring of blood lactic acid, oxygenation index and C-reactive protein levels in patients with severe pneumonia. Exp Ther Med. 2015; 10(5):1824-1828. PMC: 4665687. DOI: 10.3892/etm.2015.2770. View

Shappley C, Paik J, Saketkoo L . Myositis-Related Interstitial Lung Diseases: Diagnostic Features, Treatment, and Complications. Curr Treatm Opt Rheumatol. 2020; 5(1):56-83. DOI: 10.1007/s40674-018-0110-6. View

Dobloug G, Svensson J, Lundberg I, Holmqvist M . Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis. 2017; 77(1):40-47. DOI: 10.1136/annrheumdis-2017-211402. View

Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E, Fan E . Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307(23):2526-33. DOI: 10.1001/jama.2012.5669. View

Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E . Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med. 2019; 8(11). PMC: 6912490. DOI: 10.3390/jcm8112013. View

Jablonski R, Bhorade S, Strek M, Dematte J . Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest. 2020; 158(1):252-263. DOI: 10.1016/j.chest.2020.01.033. View

Mehta P, Agarwal V, Gupta L . High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India. Rheumatology (Oxford). 2021; 60(9):4281-4290. DOI: 10.1093/rheumatology/keab001. View

10.

Selva-OCallaghan A, Pinal-Fernandez I, Trallero-Araguas E, Milisenda J, Grau-Junyent J, Mammen A . Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018; 17(9):816-828. PMC: 11646336. DOI: 10.1016/S1474-4422(18)30254-0. View

11.

Buttgereit F, Da Silva J, Boers M, Burmester G, Cutolo M, Jacobs J . Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002; 61(8):718-22. PMC: 1754188. DOI: 10.1136/ard.61.8.718. View

12.

Li Y, Gao X, Li Y, Jia X, Zhang X, Xu Y . Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients. Front Med (Lausanne). 2020; 7:363. PMC: 7412929. DOI: 10.3389/fmed.2020.00363. View

13.

Callen J . Dermatomyositis. Lancet. 2000; 355(9197):53-7. DOI: 10.1016/S0140-6736(99)05157-0. View

14.

Huang W, Tang X . Virus infection induced pulmonary fibrosis. J Transl Med. 2021; 19(1):496. PMC: 8649310. DOI: 10.1186/s12967-021-03159-9. View

15.

Aggarwal R, Oddis C . Therapeutic advances in myositis. Curr Opin Rheumatol. 2012; 24(6):635-41. DOI: 10.1097/BOR.0b013e328358ac72. View

16.

Ge Y, Shu X, He L, Wang G, Lu X . Infection is not rare in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2021; 40(2):254-259. DOI: 10.55563/clinexprheumatol/yps7ai. View

17.

Bai Z, Shen G, Dong L . Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy. Int J Rheum Dis. 2021; 24(6):815-827. PMC: 8251775. DOI: 10.1111/1756-185X.14128. View

18.

Invernizzi R, Wu B, Barnett J, Ghai P, Kingston S, Hewitt R . The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020; 203(3):339-347. PMC: 7874329. DOI: 10.1164/rccm.202002-0460OC. View

19.

Lundberg I, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L . Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021; 7(1):86. DOI: 10.1038/s41572-021-00321-x. View

20.

Moghadam-Kia S, Oddis C . Current and new targets for treating myositis. Curr Opin Pharmacol. 2022; 65:102257. DOI: 10.1016/j.coph.2022.102257. View